SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Chairman Speech At 30Th AGM
Chairman Speech at 30th AGM29-08-2022
29-08-2022
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper Advertisement - Notice for transfer of equity shares and unclaimed dividend to the Investor Education and Protection Fund (IEPF) Account27-08-2022
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation under Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 201526-08-2022
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation under Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 201522-08-2022
Specialty drugs may push Sun Pharma's US biz beyond $2 bn by 2025
The share of specialty medicines in overall pharmaceutical spending has been consistently increasing over the past decade, from 22 per cent in 2011 to 39 per cent in 202117-08-2022
Drug makers Glenmark, Sun Pharma, Dr Reddy's recall products in US
Leading generic drug makers Glenmark, Sun Pharma, Dr Reddy's and Jubilant Cadista are recalling multiple products in the US market, the world's largest market for medicines, for various issues14-08-2022
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby furnish the details of loss of share certificates/request for issue of duplicate share certificate reported by/received from shareholders of the Company, received from our Registrar and Transfer Agent, Link Intime India Private Limited on August 13, 2022.13-08-2022
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Update On US FDA Inspection At Mohali Facility
This is to inform you that the US FDA conducted an inspection of Mohali manufacturing facility (Punjab, India) of Sun Pharmaceutical Industries Limited ('the Company') from August 3, 2022 to August 12, 2022. At the conclusion of the inspection, the US FDA issued a Form-483, with 6 observations. The Company is preparing the response to the observations, which will be submitted to US FDA within the stipulated timeline.13-08-2022
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Update On Halol Facility
This is with respect to our communication dated May 10, 2022 regarding the US FDA inspection at the Company's Halol (Gujarat) facility from April 26 to May 9, 2022 and issuance of Form-483 by US FDA with 10 observations. We now wish to inform you that the Company has received a communication from the US FDA indicating the inspection classification as 'Official Action Indicated' (OAI).13-08-2022
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Submission Of ESG Overview For Financial Year 2021 - 2022 Of Sun Pharmaceutical Industries Limited
We are submitting herewith the ESG Overview of the Company for the financial year 2021-22, which shall be released after this submission. The ESG Overview of the Company shall also be made available on the website of our Company. This is for your information and dissemination.11-08-2022